Jefferies assumed coverage of Cryoport with a Buy rating and price target of $21, up from $17. As a leader in cryogenic cold-chain logistics, Cryoport is compelling play on the industry, with commercially supported therapies and a pipeline of clinical trials offering long-duration revenue streams, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYRX:
- Cryoport price target lowered to $18 from $19 at Needham
- Cryoport ssees FY24 revenue $242M-$252M, consensus $253.22M
- Cryoport reports Q4 EPS ($1.31) with items, consensus (29c)
- Cryoport Reports Fourth Quarter and Full Year 2023 Financial Results
- CryoPort Inc Strengthens Leadership and Updates Executive Agreements
